1. Home
  2. SIFY vs GERN Comparison

SIFY vs GERN Comparison

Compare SIFY & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sify Technologies Limited

SIFY

Sify Technologies Limited

HOLD

Current Price

$13.67

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.31

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIFY
GERN
Founded
1995
1990
Country
India
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
SIFY
GERN
Price
$13.67
$1.31
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
18.6K
8.8M
Earning Date
04-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.85
EPS
N/A
N/A
Revenue
N/A
$1,065,000.00
Revenue This Year
N/A
$26.91
Revenue Next Year
$14.34
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.09
$1.04
52 Week High
$17.85
$2.01

Technical Indicators

Market Signals
Indicator
SIFY
GERN
Relative Strength Index (RSI) 35.07 41.49
Support Level $13.50 $1.24
Resistance Level $15.29 $1.46
Average True Range (ATR) 0.62 0.08
MACD -0.08 -0.02
Stochastic Oscillator 23.47 10.71

Price Performance

Historical Comparison
SIFY
GERN

About SIFY Sify Technologies Limited

Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: